Boston Scientific Loses $501 Million Stent Patent Case To Physician
This article was originally published in The Gray Sheet
Executive Summary
A Texas jury decided Feb. 12 that Boston Scientific should pay a New Jersey radiologist $501 million for infringing a patent related to drug-eluting stents
You may also be interested in...
Jury Orders Cordis To Pay $482 Mil. In Physician-Brought Stent Patent Suit
A Princeton, N.J., radiologist has received his second successful jury verdict against a drug-eluting stent maker for patent infringement and is now pursuing number three.
Jury Orders Cordis To Pay $482 Mil. In Physician-Brought Stent Patent Suit
A Princeton, N.J., radiologist has received his second successful jury verdict against a drug-eluting stent maker for patent infringement and is now pursuing number three.
Boston Scientific settles for less
Firm settles long-running patent dispute case with Princeton, N.J., radiologist Bruce Saffran on March 17 for $50 million, a significantly lower pay-out than the $501 million in damages and pre-judgment interest originally awarded to Saffran last February (1"The Gray Sheet" Feb. 18, 2008, p. 14). Boston Scientific will record the settlement charge in its first fiscal quarter. In December 2005, Saffran filed suit against Boston Scientific in the U.S. District Court for the Eastern District of Texas, alleging that the firm's Taxus and Taxus Liberté paclitaxel-eluting coronary stents infringe on one of Saffran's patents. Saffran has a similar case pending against Cypher stent-maker Johnson & Johnson